A Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Retinal oedema
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 24 Oct 2019 According to an Aerie Pharmaceuticals media release, the final patient visit is planned in Q2 2020.
- 24 Oct 2019 According to an Aerie Pharmaceuticals media release, the company plans to conduct an interim analysis (six month timepoint) of the first 20 patients before the end of this year, making preliminary data available in 2020.
- 24 Oct 2019 According to an Aerie Pharmaceuticals media release, a few additional patients are currently being screened and, if they are randomized, could bring the total number of patients in the final evaluation to a maximum of 49.